Filing Details
- Accession Number:
- 0001104659-12-047257
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-07-02 17:46:27
- Reporting Period:
- 2012-06-29
- Filing Date:
- 2012-07-02
- Accepted Time:
- 2012-07-02 17:46:27
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1316175 | Anthera Pharmaceuticals Inc | ANTH | Pharmaceutical Preparations (2834) | 201852016 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1242880 | S Christopher Henney | C/O Anthera Pharmaceuticals, Inc. 25801 Industrial Boulevard, Suite B Hayward CA 94545 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2012-06-29 | 100,000 | $0.75 | 202,429 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2012-06-29 | 100,000 | $0.75 | 100,000 | No | 4 | P | Indirect | By Christopher Scot Henney TTEE Henney QPRT Maui Trust |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct | |
| No | 4 | P | Indirect | By Christopher Scot Henney TTEE Henney QPRT Maui Trust |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.7347 to $0.7651, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.7346 to $0.7651, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Billionaire Hedge Funds
